Top Page
Galapagos
(NASDAQ:GLPG)
Galapagos (GLPG) vs. SPDR S&P 500 ETF (SPY)
Galapagos Business Overview & Revenue Model
Galapagos Earnings Call Summary
Galapagos Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 286.92M | 275.65M | 239.72M | 241.25M | 484.85M | 478.05M |
| Gross Profit | 422.74M | 240.79M | 239.72M | 241.25M | 483.22M | -45.61M |
| EBITDA | -503.23M | 43.33M | 51.04M | 3.87M | -100.93M | -170.67M |
| Net Income | -435.95M | 74.08M | 211.70M | -217.99M | -125.42M | -305.44M |
Balance Sheet | ||||||
| Total Assets | 4.13B | 4.14B | 4.36B | 4.73B | 5.19B | 5.72B |
| Cash, Cash Equivalents and Short-Term Investments | 3.58B | 3.12B | 3.68B | 4.09B | 4.70B | 5.16B |
| Total Debt | 8.81M | 11.72M | 9.60M | 21.90M | 26.86M | 29.44M |
| Total Liabilities | 1.25B | 1.24B | 1.56B | 2.21B | 2.55B | 3.05B |
| Stockholders Equity | 2.88B | 2.90B | 2.80B | 2.53B | 2.64B | 2.67B |
Cash Flow | ||||||
| Free Cash Flow | -287.04M | -402.14M | -425.24M | -537.49M | -561.71M | -518.65M |
| Operating Cash Flow | -269.36M | -320.03M | -405.97M | -500.54M | -503.83M | -427.34M |
| Investing Cash Flow | 284.55M | 220.60M | 71.19M | -1.25B | 541.24M | 757.29M |
| Financing Cash Flow | -4.47M | -4.92M | -5.00M | -1.49M | -3.88M | 22.04M |
Galapagos Technical Analysis
Galapagos Risk Analysis
Galapagos Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $3.13B | -35.33 | -28.35% | ― | 182.44% | 47.21% | |
56 Neutral | $2.54B | -25.70 | -410.78% | ― | 114.22% | 77.02% | |
52 Neutral | $2.68B | -13.24 | -34.78% | ― | ― | -34.96% | |
52 Neutral | $2.41B | -2.58 | -91.06% | ― | -32.98% | -18.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.62B | -3.91 | -27.57% | ― | 36.26% | -158.98% | |
47 Neutral | $2.24B | -4.50 | -16.45% | ― | ― | ― |
Galapagos Corporate Events
On January 5, 2026, Galapagos NV announced that, following completion of required works council consultations in Belgium and the Netherlands, its board has formally decided to wind down the company’s cell therapy activities, a move first signaled on October 21, 2025 after a strategic review and unsuccessful divestment efforts. The shutdown will affect about 365 employees across Europe, the U.S. and China and entail closing facilities in Leiden, Basel, Princeton, Pittsburgh and Shanghai, while the company concentrates resources on its remaining non-cell therapy pipeline, including the GLPG3667 TYK2 program, and seeks to reposition itself for long-term growth through transformational business development, supported by a cash and investment position of roughly €3.0 billion as of December 31, 2025 and a streamlined geographic footprint centered on Mechelen, Chicago and San Francisco.
The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
On December 18, 2025, Galapagos reported topline data from two Phase 3-enabling trials of its selective TYK2 inhibitor GLPG3667, showing that the GALARISSO dermatomyositis study met its primary endpoint, with statistically significant improvement in Total Improvement Score at week 24 versus placebo using a pre-specified 10% significance level, alongside meaningful gains on multiple secondary disease-activity measures and a favorable safety and tolerability profile. In contrast, the GALACELA systemic lupus erythematosus trial did not reach statistical significance on its primary SRI-4 dose-response endpoint at week 32, although GLPG3667 showed numerical benefits over placebo on several secondary, particularly skin-related, outcomes; with Gilead temporarily waiving certain collaboration rights, Galapagos now plans to explore strategic options, including external partnerships, to accelerate further development of GLPG3667 in dermatomyositis and potentially other autoimmune indications, while awaiting full 48-week SLE data expected in 2026 to determine the future of that program.
The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
On December 8, 2025, Galapagos NV presented new Phase 2 data from its ATALANTA-1 study at the American Society of Hematology Annual Meeting, showcasing promising results for its CAR T-cell therapy candidate, GLPG5101, in treating mantle cell lymphoma (MCL). The study demonstrated high complete response rates and minimal residual disease negativity, with a short 7-day vein-to-vein time, allowing more patients to access treatment. Despite these positive outcomes, Galapagos announced its intention to wind down its cell therapy activities, subject to consultations in Belgium and the Netherlands, while remaining open to potential acquisition proposals.
The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
On November 26, 2025, Galapagos NV announced that it received transparency notifications from Bank of America Corporation. These notifications indicated that Bank of America crossed the 5% threshold of Galapagos’ voting rights on November 12, 2025, following an acquisition, and then fell below this threshold on November 14, 2025, after disposing of these rights. This movement in voting rights reflects Bank of America’s dynamic involvement in Galapagos’ shares, which may impact the company’s shareholder structure and market perception.
The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Galapagos NV announced its financial results for the first nine months of 2025, revealing a strategic shift with the intention to wind down its cell therapy business. This decision follows a comprehensive strategic review aimed at optimizing capital allocation and supporting the company’s long-term sustainability. The wind down, if implemented, will affect approximately 365 employees and lead to the closure of several sites across Europe, the U.S., and China. Despite a significant operating loss of €462.2 million due to impairments, Galapagos maintains a robust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025. The company plans to focus on value-accretive transactions in small molecule and biologics programs, leveraging its partnership with Gilead to enhance its strategic positioning.
The most recent analyst rating on (GLPG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
On November 3, 2025, Galapagos NV announced that it will present new data for its CAR T-cell therapy candidate, GLPG5101, at the upcoming American Society of Hematology Annual Meeting in December 2025. The data, derived from Phase 2 studies, highlight the potential of GLPG5101 in treating relapsed/refractory non-Hodgkin lymphoma, demonstrating high complete response rates and low-grade toxicities. This development underscores Galapagos’ commitment to advancing cell therapy solutions and could enhance its positioning in the oncology market by addressing high unmet medical needs.
The most recent analyst rating on (GLPG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
On October 30, 2025, Galapagos NV announced significant changes to its Board of Directors to strengthen its strategic focus on business development. The appointments of Dr. Neil Johnston and Devang Bhuva as new directors aim to align the Board’s composition with the company’s strategic direction, enhancing its capacity to execute transformational business development strategies. These changes are expected to support Galapagos in creating value for shareholders and advancing its pipeline of novel medicines.
The most recent analyst rating on (GLPG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
On October 21, 2025, Galapagos NV announced its intention to wind down its cell therapy business following a comprehensive strategic review. This decision, aimed at enhancing operational efficiencies and focusing on transformational business development, was unanimously approved by the board, excluding two directors from Gilead who recused themselves. The wind-down process is expected to impact approximately 365 employees and result in the closure of several sites across Europe, the U.S., and China. The company plans to allocate its resources to areas of unmet need, with anticipated costs ranging from €100 million to €125 million in operating expenses and €150 million to €200 million in restructuring costs through 2026.
The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
On October 16, 2025, Galapagos NV announced the appointment of Fred Blakeslee as Executive Vice President and General Counsel, succeeding Valeria Cnossen. Blakeslee, who brings extensive legal expertise and experience in high-impact partnerships, is expected to play a crucial role in Galapagos’ strategic transformation and growth. His previous role at AbbVie involved leading legal teams in significant mergers and acquisitions, including the $63 billion acquisition of Allergan PLC. This leadership transition is seen as a pivotal step in advancing Galapagos’ clinical pipeline and enhancing its position in the biopharmaceutical industry.
The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.